NEW YORK (360Dx) – Oxford Immunotec today reported a 26 percent jump in its first quarter revenues, aided by its new tick-borne disease franchise.

For the three months ended March 31, total revenues came in at $21.5 million, up from $17.1 million a year ago and above the consensus Wall Street estimate of $21.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.